**Introduction**

An insignificant but prone-to-rupture coronary lesion has been named as “vulnerable plaque” (1). To elucidate the nature and mechanism of vulnerable plaque, numerous pathohistological studies have been conducted, and findings from these studies have considerably contributed to the understanding of the pathophysiology of vulnerable plaque (2-8). Meticulous analyses of coronary specimen have characterized vulnerable plaque which include a large lipid core, thin fibrous cap, expansive vessel remodeling and macrophage infiltration (2-8). These collective evidences emerge the notion that identification of vulnerable plaque with imaging modality would enable to predict the occurrence of acute coronary syndrome (ACS) and commence effective preventive therapies.

In 1990, grey-scale intravascular ultrasound (IVUS) has been developed and then used mainly for the guidance of percutaneous coronary intervention (PCI) procedures (9). One of advantages of grey-scale IVUS imaging is that it provides quantitative analysis of plaque volume in vivo. This helps interventionalists to select the optimal size of devices. In addition, grey-scale IVUS has become a tool to evaluate drug efficacy due to its quantitative and reproducible features. With regard to the ability of grey-scale IVUS for visualization of vulnerable plaques, pathohistological and clinical studies reported that attenuation of ultrasonic signals corresponds to the presence of necrotic core.

---

**In vivo imaging of vulnerable plaque with intravascular modalities: its advantages and limitations**

Satoshi Kitahara¹, Yu Kataoka¹, Hiroki Sugane², Fumiyuki Otsuka¹, Yasuhide Asaumi¹, Teruo Noguchi¹, Satoshi Yasuda¹

¹Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center, Suita, Osaka, Japan; ²Department of Cardiovascular Medicine, Chikamori Hospital, Kochi, Japan

**Contributions:** (I) Concept and design: Y Kataoka; (II) Administrative support: S Yasuda; (III) Provision of study materials or patients: Y Kataoka, S Kitahara; (IV) Collection and assembly of data: Y Kataoka, S Kitahara; (V) Data analysis and interpretation: Y Kataoka, S Kitahara; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Yu Kataoka, MD, PhD. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1, Shinmachi, Kishibe, Suita, Osaka, 564-8565, Japan. Email: yu.kataoka@ncvc.go.jp.

**Abstract:** *In vivo* imaging of plaque instability has been considered to have a great potential to predict future coronary events and evaluate the stabilization effect of novel anti-atherosclerotic medical therapies. Currently, there are several intravascular imaging modalities which enable to visualize plaque components associated with its vulnerability. These include virtual histology intravascular ultrasound (VH-IVUS), integrated backscatter IVUS (IB-IVUS), optical coherence tomography (OCT), near-infrared spectroscopy and coronary angioscopy. Recent studies have shown that these tools are applicable for risk stratification of cardiovascular events as well as drug efficacy assessment. However, several limitation exists in each modality. The current review paper will outline advantages and limitation of VH-IVUS, IB-IVUS, OCT, NIRS and coronary angioscopy imaging.

**Keywords:** Vulnerable plaque; intravascular imaging; virtual-histology intravascular ultrasound (VH-IVUS); optical coherence tomography (OCT); near-infrared spectroscopy (NIRS); integrated backscatter intravascular ultrasound (IB-IVUS), coronary angioscopy

Submitted Feb 15, 2020. Accepted for publication Apr 20, 2020.

doi: 10.21037/cdt-20-238

View this article at: http://dx.doi.org/10.21037/cdt-20-238
However, recent study showed that the positive predictive value of IVUS for detecting thin-cap fibroatheroma (TCFA) was only 19% (10). Due to this limitation of IVUS, another intravascular imaging device which visualizes plaque quality has been developed. In this review, we will summarize advantages and limitation to image vulnerable plaques with currently available modalities: virtual-histology IVUS (VH-IVUS), integrated backscatter IVUS (IB-IVUS), optical coherence tomography (OCT), near-infrared spectroscopy (NIRS) and coronary angioscopy.

**VH-IVUS**

*Tissue characterization with VH-IVUS*

VH-IVUS utilizes radiofrequency analysis of reflected ultrasound signals in a frequency domain analysis (11). It determines four tissue components: fibrous, fibrofatty, necrotic core and dense calcium. A reconstructed color-coded tissue map of plaque composition is provided and superimposed on each frame of greyscale IVUS.

*Validation of VH-IVUS imaging*

In one analysis of autopsy specimens, the accuracy of the VH-IVUS for predicting the aforementioned 4 tissue types was 79.7%, 81.2%, 85.5% and 92.8% for fibrous, fibrofatty, necrotic cores and calcium, respectively (11). Similarly, another analysis of culprit lesions in subjects who underwent PCI with directional coronary atherectomy has reported that VH-IVUS imaging identified fibrous, fibrofatty, necrotic cores and calcium with a satisfactory accuracy (87.1%, 87.1%, 88.3% and 96.5%, respectively) (12).

Brown *et al.* investigated the ability of VH-IVUS to detect TCFA by comparing with histology (13). This study showed that the diagnostic accuracy and sensitivity of TCFA on VH-IVUS was 76.5 and 83.6%, respectively. In this analysis, VH-IVUS classified 7 of 8 TCFA as thick-cap fibroatheroma. This suggests that VH-IVUS is capable of identifying a large necrotic core, but is limited to correctly evaluate thin fibrous cap.

*The ability of VH-IVUS for future cardiovascular events*

Given that plaque containing greater quantities of both necrotic and lipidic material confer an increased risk of cardiovascular events, there has been considerable interests whether VH-IVUS could predict future risks of cardiovascular events (*Tables 1, 2*). The PROSPECT (The Providing Regional Observations to Study Predictors of Events in the Coronary Tree) trial is the largest observational study which investigated the predictive ability of TCFA on VH-IVUS for cardiovascular events (14). This study enrolled a total of 697 ACS patients. All three major coronary arteries were imaged by VH-IVUS. VH-IVUS-derived TCFA was defined as more than 30 degrees of the necrotic core abutted the lumen in 3 or more consecutive frames. In this study, 596 VH-IVUS derived TCFA were identified in 313 patients. During a median follow-up period of 3.4 years, patient-level analysis demonstrated VH-IVUS derived TCFA as an independent predictor of subsequent non-culprit lesion-related major adverse cardiovascular events (MACEs) [hazard ratio (HR) =3.35, 95% confidence interval (CI): 1.77–6.36, P<0.001], in addition to insulin-requiring diabetes (HR =3.32, 95% CI: 1.43–7.72, P=0.005), baseline plaque burden >70% (HR =5.03, 95% CI: 2.51–10.11, P<0.001) and a minimal luminal area ≤4.0 mm$^2$ (HR =3.21, 95% CI: 1.61–6.42, P=0.001). Similar findings were observed even at lesion-level analysis. Of note, the frequency of non-culprit lesion-related MACE increased in association with the number of these VH-IVUS derived measures (no feature: 0.3%, 1 feature: 4.8%, 2 features: 10.5%, 3 features: 18.2%, P<0.001).

The VIVA (VH-IVUS in Vulnerable Atherosclerosis) study analyzed the association of VH-IVUS derived plaque features with clinical outcomes in patients with coronary artery disease (CAD) (15). Three major coronary arteries in 170 patients with CAD were monitored by VH-IVUS. Compared to PROSPECT study, this study used different definition of VH-IVUS derived TCFA, which included plaque burden >40% and confluent necrotic core >10% plaque cross-sectional area, in contact with vessel lumen for 3 consecutive frames. In this study with a median follow-up of 625 days, both patient-based and lesion-based analyses elucidated that VH-IVUS-derived TCFA was the only plaque phenotype associated with the occurrence of MACE (patient-based analysis: HR =7.53, 95% CI: 1.12–50.55, P=0.038, lesion-based analysis: HR =4.43, 95% CI: 1.50–13.18, P=0.007).

The ATHEROREMO-IVUS (the European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis-Intravascular Ultrasound) study is a single-center observational study of 581 ACS or stable CAD subjects (16). VH-IVUS was used to interrogate non-culprit vessel. The primary outcome was the occurrence of MACE which included non-culprit lesion
related or indeterminate mortality, ACS or unplanned coronary revascularization. In this study, the presence of TCFA (HR =1.98, 95% CI: 1.09–3.60, P=0.02) and plaque burden >70% (HR =2.90, 95% CI: 1.60–5.25, P<0.001) predicted the occurrence of MACE. Interestingly in particular, the presence of TCFA with plaque burden >70% was associated with an elevated risk of MACE within (P=0.011) and after 6 months (P<0.001).

Serial VH-IVUS imaging has provided insights into the natural history of atheroma instability. Kubo et al. reported changes in a variety of plaque phenotypes in 99 patients (20). There were 20 TCFA at baseline. During the follow-up period, its healing was observed in 75% of them. Namely, 13 and 2 TCFA became thick-cap fibroatheroma and fibrous plaque, respectively. Furthermore, the remaining 25% of TCFA did not change. In this analysis, 12 newly developed TCFA were observed. This vulnerable feature occurred at pathological intimal thickening or thick-cap fibroatheroma at baseline. As such, serial VH-IVUS imaging elucidated the formation of TCFA and its spontaneous healing in vivo. This observation suggests that all TCFA does not necessarily cause coronary event but remains quiescent.

### Drug efficacy assessment study with VH-IVUS (Tables 1,2)

Nasu et al. compared serial change in plaque composition on VH-IVUS between stable CAD patients receiving fluvastatin and those without it for 12 months (17). Under the therapy, LDL-C level was significantly lowered by 98.1±12.7 mg/dL. Additionally, the use of fluvastatin was associated with favourable modulation of plaque components, reflected by a significant reduction of fibro-fatty volume (80.1±57.9 mm$^3$ at baseline vs. 32.5±27.7 mm$^3$ at follow-up, P<0.0001) and a significant increase in fibrous tissue volume (146.5±85.6 mm$^3$ at baseline vs. 163.3±94.5 mm$^3$ at follow-up, P<0.0001). In contrast to these findings, in patients who did not receive fluvastatin, a significant increase in volumes of fibro-fatty, necrotic core and calcium materials was observed. Linear regression analysis identified the relationship of changes in LDL-C (R=0.703, P<0.0001) and high-sensitivity c-reactive protein levels (R=0.357, P=0.006) with change in fibro-fatty volume.

The SATURN (The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) trial is a largest serial IVUS study which compared two high-intensity statin regimens on coronary
atherosclerosis in 1039 stable CAD patients (21). Serial VH-IVUS imaging was used in 71 patients for sub-analysis of analyzing plaque stabilization effects of high-intensity statin (18). Fibro-fatty tissue volume significantly reduced (23.1 to 13.4 mm$^3$, P<0.001) and calcium tissue volume increased (1.2 to 2.1 mm$^3$, P=0.002). In addition, on lesion-based analysis, the use of high-intensity statin reduced the number of pathological intimal thickening lesions (67% vs. 38%, P=0.001) (18).

IBIS-4 (Integrated Biomarker Imaging Study-4) study investigated the effect of 10 mg rosuvastatin of atheroma progression and VH-IVUS derived plaque components in 146 non-infarct-related coronary arteries of 82 STEMI patients (19). Predictably, 10 mg rosuvastatin significantly lowered LDL-C level (median: 127 vs. 73 mg/dL, P<0.001) with an increase in HDL-C level (median: 42 vs. 46 mg/dL, P<0.001) during the 13-month follow-up period. Moreover, a significant reduction of percent atheroma volume was observed under this therapeutic regimen [-0.9% (95% CI: -1.56% to -0.25%, P=0.007)]. While 10 mg rosuvastatin was associated with an increased percent volume of dense calcium [1.28% (95% CI: 0.66% to 1.9%), P<0.001] and a decrease in percent volume of fibrous tissue [-1.38% (95% CI: -2.28% to -0.47%), P=0.003], it did not affect necrotic core [-0.05% (95% CI: -1.05% to 0.96%), P=0.926], which was inconsistent to that in other pre-clinical and pathohistological studies. Relatively short follow-up period (12–18 months) may make it difficult to detect favourable efficacy of a statin on modifying necrotic core in vivo.

### Consideration of limitation of VH-IVUS imaging

Recent data raise questions about the accuracy of VH-IVUS to detect necrotic core. In a swine atherosclerosis model, there was no correlation between VH-IVUS-identified necrotic core and histology (22). Swine necrotic core lack cholesterol crystals, making them inherently different from human necrotic cores. However, this data arise concern to use VH-IVUS imaging for drug efficacy assessment trial. The GLAGOV (Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound) trial is a recent IVUS study to investigate anti-atherosclerotic property of evolocumab injection on coronary atheroma in 968 stable CAD patients who have already been treated with tolerable maximally intensity statin (23). This trial demonstrated that evolocumab induced greater regression of coronary atherosclerosis. VH-IVUS was used as sub-study in 331 patients (24). Even in this cohort, reduction of LDL-C levels and regression of coronary atheroma was observed with similar extent to main findings of the GLAGOV trial. Despite these favourable observations, there were no significant differences in VH-IVUS derived plaque components [calcium (1.0±0.3 vs. 0.6±0.3 mm$^3$, P=0.49), fibrous (3.0±0.6 vs. 2.4±0.6 mm$^3$, P=0.49), fibrofatty (5.0±1.0 vs. 3.0±1.0 mm$^3$, P=0.49), and necrotic (0.6±0.5 vs. 0.1±0.5 mm$^3$, P=0.49)] volumes

---

**Table 2 Clinical studies with VH-IVUS imaging—evaluation of drug efficacy**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Therapy</th>
<th>Outcomes</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasu et al. (17)</td>
<td>80 patients with stable CAD</td>
<td>Fluvastatin vs. no statin use</td>
<td>Percent change in atheroma volume</td>
<td>Patients treated with fluvastatin were more likely to exhibit an increase in fibrous tissue volume (P=0.03) and a decrease of fibro-fatty (P&lt;0.0001) and necrotic core volumes (P=0.004). Change in dense calcium volume was smaller in fluvastatin group (P=0.03)</td>
</tr>
<tr>
<td>Puri et al. (18)</td>
<td>71 subjects with CAD</td>
<td>80 mg atorvastatin vs. 20 mg rosuvastatin</td>
<td>Change in VH-IVUS derived plaque composition</td>
<td>High-intensity statin use was associated with a reduction in fibro-fatty tissue volume (P&lt;0.001) and an increase in dense calcium tissue volume (P=0.002)</td>
</tr>
<tr>
<td>Räber et al. (19)</td>
<td>82 STEMI patients</td>
<td>10 mg rosuvastatin</td>
<td>Change in percent atheroma volume and VH-IVUS derived plaque composition</td>
<td>During the 13-month follow-up period, 10mg rosuvastatin induced a significant reduction of percent atheroma volume [-0.9% (95% CI: -0.9% to -0.5%)]. In addition, an increased percent volume of dense calcium [+1.28% (95% CI: 0.66% to 1.9%), P&lt;0.001] and a decrease in percent volume of fibrous tissue [-1.38% (95% CI: -2.28 to -0.47), P=0.003] were observed. This therapy did not significantly modify volume of necrotic core [-0.05% (95% CI: -0.05 to 0.06), P=0.926]</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; VH-IVUS, virtual histology-intravascular ultrasound.
between evolocumab and control groups. The lack of any demonstrable differences between the treatment groups in VH-IVUS analysis of the GALOGOV trial suggests the limitation of VH-IVUS for drug efficacy assessment trial.

The acquisition of VH-IVUS images is gated at the R wave of the electrocardiography signal, which fails to allow for VH-IVUS imaging to be performed upon the frames acquired within each R–R interval. Variability in a patient’s heart rate at different time points results in a degree of horizontal bias during serial VH-IVUS imaging. These cause different numbers of frames at baseline and follow-up imaging, which is not adequate for analyzing the exactly same segment in the clinical trials of drug efficacy evaluation.

**IB-IVUS**

*Tissue characterization and validation of IB-IVUS imaging*

IB-IVUS is another imaging modality to evaluate compositional features of coronary atheroma in vivo. This imaging technique utilizes time-domain information through the acquired radiofrequency signals (25). *Ex vivo* validation study showed that IB signals could differentiate different types of plaque tissues including fibrous, calcification and lipid pool. The accuracy of IB-IVUS to detect fibrous, lipid-rich and fibrocalcific plaques was 93%, 90% and 96%, respectively (25,26). Another study reported that the positive predictive value of IB-IVUS for TCFA was 50.0% (27).

**Drug efficacy assessment study with IB-IVUS (Table 3)**

Kawasaki, *et al.* compared 6-month changes in IB-IVUS derived plaque features in 52 patients with pravastatin, atorvastatin or diet therapy (28). Non-culprit segment was selected for this analysis. On serial IB-IVUS imaging, the use of pravastatin and atorvastatin was associated with a significant increase in fibrous volume and a reduction of lipid volume compared to subjects receiving diet therapy. Similar findings were reported by another study analyzing 42 patients with stable CAD (29). Following the 9-month 4 mg pitavastatin use, a significant increase in fibrous volume index (P=0.01) and as well as a significant decrease in lipid volume index (P=0.03) were observed. Details in other studies with IB-IVUS for the assessment of drug efficacy are summarized in Table 3 (30-35).

**Consideration of limitation of IB-IVUS imaging**

Evidence is limited to show the association of IB-IVUS derived plaque features with cardiovascular events.

**OCT imaging**

*Imaging of plaque microstructures*

OCT uses near-infrared light which enables to provide imaging of atherosclerotic plaques in coronary artery (36,37). High resolution imaging is one of the advantages of OCT imaging. Its resolution is up to 10 μm in an axial resolution and to 20 μm in a lateral resolution, which is approximately 10 times higher compared to that of IVUS. This distinct feature of OCT enables to generate high quality imaging of plaque microstructures such as thin fibrous cap, microchannel, accumulation of lipid and macrophages (36,37).

There are numerous studies which elucidated features of plaque microstructures in patients with CAD. In 30 subjects with acute myocardial infarction, thin fibrous cap, plaque rupture, thrombus and TCFA were observed, in line with findings from pathohistological studies (38). In another study, the presence of vaso vasorum at culprit lesions was associated with thinner fibrous cap, a higher frequency of TCFA and a higher c-reactive protein level (39). OCT has been shown to identify differences in plaque features of subjects with ST-elevation myocardial infarction, non-ST-elevation ACS and stable angina pectoris (37). TCFA was defined as a plaque with lipid arc >90 degrees and its fibrous cap thickness <65 μm. The frequency of TCFA was significantly higher in patients with ST-elevation myocardial infarction and non-ST-elevation ACS compared to that in subjects with stable angina pectoris (72%, 50%, and 20%, respectively, P=0.012). Furthermore, patients with ST-elevation myocardial infarction and non-ST-elevation ACS were more likely to exhibit thinner fibrous cap (47.0, 53.8 and 102.6 μm, respectively, P=0.034).

**Validation of OCT imaging**

*Ex vivo* validation study has been conducted to compare OCT images with histological features by using 357 atherosclerotic arterial segments of autopsy specimens (40). Fibrous plaques were characterized by homogeneous, signal-rich regions. Fibrocalcific plaques was defined as well-delineated, signal-poor regions with sharp borders. Lipid-rich plaques was characterized by signal-poor regions.
with diffuse borders. A sensitivity and specificity for fibrous plaque is ranging from 71% to 79% and 97% to 98%, respectively. Those for fibrocalcific plaques and lipid-rich plaques was from 95% to 96% and 97%, and 90% to 94% and 90% to 92%, respectively. The interobserver and intraobserver reliabilities of OCT assessment were high (kappa values of 0.88 and 0.91, respectively). Another ex vivo validation showed an excellent correlation between fibrous cap thickness on OCT and histology ($r=0.90$) at 35 lipid-rich plaques of 102 coronary segments in 38 human cadavers (41).

The ability of OCT imaging for future cardiovascular events (Tables 4, 5)

Xing et al. investigated the association of lipid-rich plaques at non-culprit lesions with MACE (cardiac death, acute myocardial infarction, and ischemia-driven revascularization) (48). This analysis included 1,474 patients with CAD who received OCT imaging during PCI. Study subjects were prospectively enrolled at 20 cites across 6 countries. OCT derived lipid-rich plaque was identified
Table 4 Clinical studies with OCT imaging—prediction of future cardiovascular events

<table>
<thead>
<tr>
<th>Authors</th>
<th>Sites</th>
<th>Population</th>
<th>OCT-derived measure</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xing et al. (42)</td>
<td>20 sites across 6 countries</td>
<td>1,471 patients with CAD (ACS =584, stable CAD =887)</td>
<td>lipid plaque with its arc of &gt;1 quadrant</td>
<td>Subjects with lipid-rich plaque exhibited an increased risk of non-culprit lesion related major adverse cardiac events (7.2% vs. 2.6%, P=0.033). Multivariate analysis demonstrated the presence of lipid-rich plaque as an independent predictor of non-culprit lesion related major adverse cardiac events included lipid-rich plaque (risk ratio =2.061, 95% CI: 1.050–4.044, P=0.036). Longer lipid lengths (9.9±3.6 vs. 7.9±4.6, P&lt;0.001), wider maximal lipid arcs (240.9±78.4 vs. 205.1±69.3, P=0.023) and smaller minimum lumen areas (3.71±2.18 vs. 5.22±2.87, P=0.003) were additional features of lipid-rich plaque causing MACE.</td>
</tr>
<tr>
<td>Prati et al. (43)</td>
<td>11 sites</td>
<td>1,003 patients with suspected CAD</td>
<td>Lipid arc &gt;180°, fibrous cap thickness &lt;75 μm, macrophages minimum lumen area &lt;3.5 mm²</td>
<td>Lipid arc &gt;180° (HR =2.4, 95% CI: 1.2–4.8, P=0.017), fibrous cap thickness &lt;75 μm (HR =4.7, 95% CI: 2.4–9.0, P&lt;0.001), macrophage (HR =2.7, 95% CI: 1.2–6.1, P=0.027) and minimum lumen area &lt;3.5 mm² (HR =2.1, 95% CI: 1.1–4.0, P=0.032), predicted the occurrence of cardiac events (= cardiac death and target segment myocardial infarction).</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.

Table 5 Clinical studies with OCT imaging—evaluation of drug efficacy

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Therapy</th>
<th>Outcomes</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Komukai et al. (44)</td>
<td>70 patients with unstable angina pectoris</td>
<td>5 vs. 10 mg atorvastatin</td>
<td>Change in fibrous cap thickness</td>
<td>A significant increase in fibrous cap thickness was observed under 20 mg atorvastatin (69% vs. 17%; P&lt;0.001). The increase in fibrous cap thickness was associated with the decrease in LDL-C level (R=−0.450; P&lt;0.001), malondialdehyde-modified LDL (R=−0.283; P=0.029), high-sensitivity CRP (R=−0.276; P=0.033), and MMP-9 (R=−0.502; P&lt;0.001), and the decrease in macrophage grade (R=−0.415; P=0.003)</td>
</tr>
<tr>
<td>Kataoka et al. (45)</td>
<td>275 patients with stable CAD</td>
<td>Standard therapy without a statin vs. low-dose statin vs. high-dose statin</td>
<td>Fibrous cap thickness</td>
<td>Patients receiving high-dose statin exhibited plaques with a smaller lipid arc (P=0.02) and a greater fibrous cap thickness (P=0.01)</td>
</tr>
<tr>
<td>Kataoka et al. (46)</td>
<td>280 patients with CAD</td>
<td>Statin therapy</td>
<td>Fibrous cap thickness</td>
<td>Achieving on-treatment LDL-C &lt;50 mg/dL was associated with thicker fibrous cap (P=0.01) and a smaller frequency of lipid plaques (P=0.01)</td>
</tr>
<tr>
<td>Kataoka et al. (46)</td>
<td>40 AMI patients who received PCI</td>
<td>Statin therapy vs. no statin use</td>
<td>Fibrous cap thickness</td>
<td>Greater percent change in fibrous cap thickness was observed in patients treated with a statin (188%±64% vs. 117%±39%, P&lt;0.01). Of note, plaques with its fibrous cap thickness &lt; median more likely exhibited its increase at a greater extent compared to lesions with fibrous cap &gt; median</td>
</tr>
<tr>
<td>Habara et al. (47)</td>
<td>63 patients with CAD</td>
<td>Combination of fluvastatin + ezetimibe versus fluvastatin alone for 9 months</td>
<td>Change in fibrous cap thickness</td>
<td>The change in the fibrous cap thickness was significantly greater in the ezetimibe + fluvastatin group (0.08±0.08 vs. 0.04±0.06 mm, P&lt;0.001)</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.
in 33.6% of study subjects. During the follow-up period (median = 2 years), the presence of lipid-rich plaque was associated with an increased risk of non-culprit lesion related MACE (7.2% vs. 2.6%, P=0.033). On multivariate analysis, independent predictors of non-culprit lesion related MACE included lipid-rich plaque (risk ratio = 2.061, 95% CI: 1.050–4.044, P=0.036), ACS (risk ratio = 2.538, 95% CI: 1.246–5.173, P=0.010) and interruption of statin use >1 year (risk ratio = 4.517, 95% CI: 1.923–10.610, P=0.001). Further OCT analysis elucidated that lipid-rich plaque associated with non-culprit lesion related MACE was more likely to exhibit longer lipid lengths (9.9±3.6 vs. 7.9±4.6, P<0.001), wider maximal lipid arcs (240.9±78.4 vs. 205.1±69.3, P=0.023) and smaller minimum lumen areas (3.71±2.18 vs. 5.22±2.87, P=0.003) compared to that without any events. The CLIMA (Relationship between coronary plaque morphology of the left anterior descending artery and long-term clinical outcome) study is a prospective observational, multi-center registry (42). This study analyzed 1,776 lipid plaques at proximal segment of left anterior descending artery in 1,003 patients. OCT-derived plaque features associated with cardiac events (= cardiac death and target segment myocardial infarction) included minimum lumen area <3.5 mm² (HR =2.1, 95% CI: 1.1–4.0, P=0.032), fibrous cap thickness <75 μm (HR =4.7, 95% CI: 2.4–9.0, P=0.001), lipid arc >180° (HR =2.4, 95% CI: 1.2–4.8, P=0.017) and macrophage (HR =2.7, 95% CI: 1.2–6.1, P=0.027). Of note, lesions containing all of these plaque features exhibited the largest risk of cardiac events (HR =7.54, 95% CI: 3.1–18.6, P<0.001). The representative case is shown as Figure 1 (43).

Drug efficacy assessment study with OCT imaging (Table 3)

The EASY-FIT (Effect of Atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque assessed by OCT) trial is a prospective randomized single-center study which investigated and compared the efficacy of 20 and 5 mg atorvastatin on plaque microstructures in 70 patients with unstable angina pectoris (49). A lower level of on-treatment LDL-C was achieved in subjects taking 20 mg atorvastatin compared to those with 5 mg one. In addition, fibrous cap thickness significantly increased under the use of 20 mg atorvastatin (69% vs. 17%, P<0.001). Interestingly in particular, an increase in fibrous cap thickness was correlated to a decrease in LDL-C level (R=-0.450, P<0.001).

One retrospective study analyzed OCT plaque features in 275 patients with CAD receiving PCI (44). Compared to subjects who did not receive a statin, statin use with a greater intensity was associated with thicker fibrous cap (P=0.01) and a lower frequency of TCFA (P<0.001) and vaso vasorum (P=0.01). Another retrospective analysis investigated the association of on-treatment LDL-C level with plaque microstructures (45). Achieving a lower on-treatment LDL-C level was inversely associated with thickness of fibrous cap. Moreover, in patients with on-treatment LDL-C <50 mg/dL, the prevalence of TCFA was lowest compared to others. These favourable efficacies of lowering LDL-C with a statin was consistently observed in various subsets except diabetic patients.

Habara et al. compared the efficacy of ezetimibe + fluvastatin vs. fluvastatin alone on plaque microstructures in 63 patients with CAD (46). Predictably, combination therapy was associated with a greater reduction of LDL-C level at 9 months (−34.0±32.0 vs. −8.3±17.4 mg/dL, P<0.001). OCT imaging analysis demonstrated a greater increase in fibrous cap thickness in the ezetimibe + fluvastatin group (0.08±0.08 vs. 0.04±0.06 mm, P<0.001). This result supports favourable anti-atherosclerotic efficacies of ezetimibe, which could account for better cardiovascular outcomes in subjects receiving both ezetimibe and statin in recent clinical trial (47).

Consideration of limitation of OCT imaging

Since penetration depth of OCT imaging is only 2 to 3 mm, it is not suitable for evaluation of plaques in large arteries (coronary diameter >4 mm), and it can not measure plaque area and volume. It is necessary to continuously infuse contrast medium or low-molecular-weight dextran during its pullback because red blood cell causes signal attenuation. Therefore, this modality is not appropriate for imaging of aorto-ostial stenosis. Since the new frequency-domain OCT system enables to acquire 100 frames/sec with its pullback speed up to 20 mm/sec, it need only bolus injection of contrast medium or low-molecular-weight dextran for imaging (50).

Another limitation is that interpretation of images is quite subjective. In particular, evaluation of lipid plaque component is always challenging. Furthermore, measurement of fibrous cap thickness varies in each individual. One study investigated the way to improve reproducibility of lipid arc and fibrous cap measurements (51). Intraclass correlation coefficients of these measures between two independent physicians were 0.76 and 0.56, respectively. After discussion, consensus and developing
algorithms in physicians, reproducibility of measurements was improved, reflected by intraclass correlation coefficients at 0.82 and 0.88, respectively. This study indicates that mutual discussion and consensus are mandatory for accurate and reproducible OCT analysis. In the future, novel technologies such as machine learning and/or artificial intelligence could be a solution to improve OCT measurement.

Jia et al. established the criteria of OCT-defined plaque erosion (52). OCT-defined plaque erosion is defined and categorized according to the absence of fibrous cap disruption and the presence of thrombus. This OCT-based diagnostic approach of plaque erosion is attractive. However, correct diagnosis of plaque erosion \textit{in vivo} by using OCT is not easy in the clinical settings. Given that the presence of luminal thrombus hampers the penetration of light into the underlying plaque, it is difficult to assess features of plaques behind attached thrombus. We experienced one ACS case diagnosed as plaque erosion according to OCT-based criteria (53) (Figure 2). However, considering clinical characteristics including the presence of atrial fibrillation enables to diagnosis as coronary embolism but not plaque erosion. As such, meticulous evaluation of plaques suspected with its erosion is required.

Figure 1 The recurrence of ACS due to progression of lipid-rich plaque containing cholesterol crystal (28). (A) A 60-year-old man with ST-segment elevation myocardial infarction received DES implantation at the middle segment of LAD (dotted line). There was a mild residual stenosis in LAD (red arrow). [1–4] correspond to OCT images in (B). (B) OCT imaging visualized the presence of lipid-rich plaque (L) harbouring cholesterol crystal (white triangle). (C) One year later, non-ST-segment elevation myocardial infarction occurred due to the progression of lipid-rich lesions with cholesterol crystal despite statin therapy (red arrow). ACS, acute coronary syndrome; DES, drug-eluting stent; LAD, left anterior descending artery; OCT, optical coherence tomography.
NIRS imaging

Quantitative assessment of lipid atheroma on NIRS

NIRS imaging uses the technique of specifically identifying lipidic plaque components within vessel wall according to a spectroscopic algorithm (54,55). NIRS has the ability to identify cholesterol within atherosclerotic plaques based on specific spectra of cholesterol. According to an algorithm constructed with pathohistological data, this modality shows the probability whether the imaged atherosclerotic lesions harbour a lipid core plaque. The probability of lipid core plaque is shown as the following four different colors; red (probability <0.57), orange (0.57 ≤ probability <0.84), tan (0.84 ≤ probability <0.98) and yellow (probability ≥0.98). The lipid core burden index (LCBI) is calculated by the proportion of pixels with the probability of a lipid plaque above 0.6 per million (‰, multiplied by 1,000). NIRS provides two measures which include mean LCBI and maximum LCBI at 4 mm segment (LCBI_{max 4 mm}). Mean LCBI is the fraction of pixels above probability of 0.6 in a region of interest. LCBI_{max 4 mm} exhibits the maximum LCBI at 4-mm segment within a region of interest.
Validation of chemogram on NIRS imaging

The ability of NIRS imaging to reveal plaque compositions associated with its instability has been analyzed by using 199 samples of 5 human aortic specimens (56). In this analysis, 35 of 39 lesions with lipid pools and 56 of 60 lesions without lipid pools were identified by NIRS imaging (sensitivity = 90%, specificity = 93%). This modality detected other unstable plaque features including thin fibrous cap and the presence of inflammatory cells (thin fibrous caps: sensitivity = 77%, specificity = 93%, inflammatory cells: sensitivity = 84%, specificity = 91%) (56). Gardner et al. performed ex vivo validation study using human coronary specimens (57). This study analyzed 212 coronary segments of 84 autopsy hearts by NIRS imaging and histopathological evaluation of sections taken at 2-mm intervals. The algorithm established from the first 33 hearts was effective to identify lipid core plaques with a receiver operating characteristics curve area of 0.80 (95% CI: 0.76–0.85). Additionally, a higher LCBI corresponded to the presence of any fibroatheroma with an area under the curve of 0.86 (95% CI: 0.81–0.91). Another validation study of the NIRS algorithm is the SPECTACL (SPECTroscopic Assessment of Coronary Lipid) study with 106 patients with CAD (58). The investigators compared acquired spectra with NIRS signal in autopsy coronary specimens. On multivariate statistics, spectral similarity was observed in 40 of 48 scans (83% success rate, 95% CI: 70–93%). Additionally, 58% of 60 scans identified the presence of lipid core plaques.

Recently, the relationship of NIRS/IVUS derived measures with coronary fibroatheroma was analyzed in 116 coronary artery specimens of 51 autopsied hearts (59). LCBI, IVUS derived plaque volume and histological grading according to modified American Heart Association criteria were investigated at each 2-mm block sections (n=2,070) and lesions (n=102). On a block-level analysis, histological complexity significantly increased in association with the extent of plaque burden and LCBI (P<0.001 for trend for plaque burden and LCBI). Furthermore, coronary fibroatheroma exhibited the highest remodeling index compared to other types of plaques (P=0.001 for trend). Receiver-operating curve analysis elucidated plaque burden, LCBI and remodeling index as significant features associated with the presence of fibroatheroma (c-indices: 0.675, 0.712 and 0.672, respectively). Collectively, these validation studies suggest that NIRS imaging is feasible with reasonable sensitivity and specificity to assess the extent of lipidic materials in vivo.

The ability of NIRS imaging for future cardiovascular events

Several single-center studies have been conducted to investigate the prognostic value of LCBI from 2014 to 2017 (60–63) (Tables 6,7). Oemrawsingh et al. analyzed 203 CAD patients in which their non-culprit vessel was imaged by NIRS (Tables 4,5) (67). Subjects with LCBI above median value of LCBI (43.0) was associated with an increased risk of MACE (= all-cause mortality, nonfatal ACS, stroke and unplanned coronary revascularization) compared to those with LCBI below its median value (16.7% vs. 4.0%, log-rank, P=0.003). Even after adjusting baseline clinical characteristics (age, sex, hypercholesterolemia, diabetes, hypertension, history of myocardial infarction, peripheral artery disease and a history of PCI), there was a 4.04 (95% CI: 1.33–12.29, P=0.01) greater likelihood of experiencing MACE during one-year observational period. Another analysis from the Spectrum NIRS-IVUS Registry included 121 CAD patients monitored by NIRS imaging (Tables 4,5) (60). Cox regression analysis showed maxLCBI_{max} ≥ 400 at non-culprit segment as one-year occurrence of MACE (HR =10.2, 95% CI: 3.4–30.6, P<0.001). Four-year follow-up data has been presented by Schuurman et al. (61). They analyzed NIRS data at non-culprit vessel of 275 patients with CAD. During a median follow-up of 4.1 years, there was a statistically significant continuous relationship between higher LCBI_{max} values and a higher risk of MACEs. Multivariate analysis continued to demonstrate the association of LCBI_{max} with MACE (HR =1.19 per 100 units increase in LCBI, 95% CI: 1.07–1.32, P=0.001). While these findings indicate the potential of NIRS to predict future events, there are some limitation which includes small size of study population and single center study. To overcome these limitations of published studies, the LRP (Lipid Rich Plaque) Study has been recently conducted (Tables 6,7) (63). The LRP study is a prospective cohort study which enrolled 1,563 subjects with CAD. NIRS imaging was conducted at non-stented segment with its length above 50 mm. This imaging procedure was performed from at least two major coronary arteries. Patient-based analysis showed that subjects with maxLCBI_{max} ≥ 400 predicted non-culprit lesion-related MACE (adjusted HR =1.89, 95% CI: 1.26–2.83, P=0.0021). Segment-based analysis also revealed that segment exhibiting maxLCBI_{max} ≥ 400 associated with a greater frequency of MACE (adjusted HR =3.39, 95% CI: 1.85–6.20, P<0.0001). Figure 3 illustrates a representative
Table 6 Clinical studies with NIRS imaging—prediction of future cardiovascular events

<table>
<thead>
<tr>
<th>Authors</th>
<th>Cites</th>
<th>Population</th>
<th>NIRS-derived measure</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oemrawsingh et al.</td>
<td>Single center</td>
<td>203 patients with CAD (ACS =95, stable CAD =108)</td>
<td>LCBI at non-culprit vessel (at least 40 mm in length, % diameter stenosis &lt;50%)</td>
<td>LCBI &gt;43 (median) predicted the occurrence of one-year MACE (= all-cause death, non-fatal ACS, stroke, unplanned coronary revascularization): HR =4.04, 95% CI: 1.33–12.29, P=0.01</td>
</tr>
<tr>
<td>Madder et al.</td>
<td>Single center</td>
<td>121 patients with suspected CAD (ACS =103, stable CAD =18)</td>
<td>Max4 mmLCBI at non-stented segment</td>
<td>Max4 mmLCBI &gt;400 was associated with MACCE (all-cause mortality, non-fatal ACS, acute cerebrovascular events) during follow-up: HR =10.2, 95% CI: 3.4–30.6, P&lt;0.001</td>
</tr>
<tr>
<td>Schuurman et al.</td>
<td>Single center</td>
<td>275 patients with CAD (ACS =117, stable CAD =158)</td>
<td>Max4 mmLCBI at non-culprit vessel (at least 40 mm in length, % diameter stenosis &lt;50%)</td>
<td>Each 100 units increase of Max4 mmLCBI was associated with a 19% increase in MACE (= all-cause death, non-fatal ACS, unplanned revascularization): HR =1.19, 95% CI: 1.07–1.32, P=0.001</td>
</tr>
<tr>
<td>Danek et al.</td>
<td>Single center</td>
<td>239 patients with CAD (ACS =93, stable CAD =146)</td>
<td>LCBI at non-culprit vessel</td>
<td>LCBI &gt;77 predicted 5-year MACE (cardiac mortality, ACS, stroke, unplanned revascularization): HR =14.05, 95% CI: 2.47–133.51, P=0.002</td>
</tr>
<tr>
<td>Waksman et al.</td>
<td>44 cites from 6 countries</td>
<td>1,563 patients with CAD (ACS =974, stable CAD =589)</td>
<td>Max4 mmLCBI at lesion containing maxLCBI ≤400</td>
<td>Patient-based analysis: Max4 mmLCBI &gt;400 was associated with non-culprit lesion related MACE (= cardiac death, cardiac arrest, non-fatal MI, ACS, revascularization): adjusted HR =1.89, 95% CI: 1.26–2.83, P=0.021. Segment-based analysis: Max4 mmLCBI &gt;400 was associated with non-culprit lesion related MACE: adjusted HR =3.39, 95% CI: 1.85–6.20, P&lt;0.0001</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular events; NIRS, near-infrared spectroscopy; LCBI, lipid core burden index.

Table 7 Clinical studies with NIRS imaging—evaluation of drug efficacy

<table>
<thead>
<tr>
<th>Authors</th>
<th>Population</th>
<th>Drug</th>
<th>Outcome</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kini et al. (65)</td>
<td>87 patients with multivessel CAD</td>
<td>Standard vs. intensive statin (20 mg rosuvastatin)</td>
<td>Max4 mmLCBI at lesions with its percent diameter stenosis &gt;70% and fractional flow reserve &lt;0.8</td>
<td>Intensive statin therapy was associated with a significant reduction of LCBI_{max4 mm} (median percent change: −32.2% vs. −0.6%, P=0.02)</td>
</tr>
<tr>
<td>Dohi et al. (66)</td>
<td>87 patients with multivessel CAD</td>
<td>Standard vs. intensive statin (20 mg rosuvastatin)</td>
<td>Max4 mmLCBI at lesions with its percent diameter stenosis &gt;70% and fractional flow reserve &lt;0.8</td>
<td>Max4 mmLCBI did not change at lesions with Max4 mmLCBI under the use of 20 mg rosuvastatin. By contrast, LCBI_{max4 mm} significantly reduced at lesions with LCBI_{max4 mm} ≥500 under 20 mg rosuvastatin use (median: 703 at baseline, 399 at 7 weeks, P=0.004)</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular events; NIRS, near-infrared spectroscopy; LCBI, lipid core burden index.

case which showed the occurrence of ACS at lesion containing maxLCBI_{max4 mm} ≥400. NIRS imaging could be an applicable tool in the clinical settings for risk stratification in patients with CAD.

**Drug efficacy assessment study with NIRS imaging**

The YELLOW (Reduction in Yellow Plaque by Intensive Lipid Lowering Therapy) trial is the first study to use NIRS for the evaluation of drug efficacy in patients with CAD (64) (Tables 6, 7). This trial was a prospective, randomized study which enrolled 86 patients with multivessel obstructive CAD. Study subjects were randomized to standard or intensive statin therapy. The target segment for imaging was the lesion with its percent diameter stenosis ≥70% and fractional flow reserve <0.8. After 7 weeks of the therapy,
greater reduction of LDL-C level was observed in subjects receiving intensive statin therapy (20 mg rosuvastatin) (58.4±26.3 vs. 81.9±27.9 mg/dL, P<0.001). Serial greyscale IVUS imaging showed that coronary atheroma volume at 7 weeks after the therapy did not differ between two groups. However, on NIRS imaging analysis, intensive statin therapy was associated with a significant reduction of LCBI
\[\text{max 4 mm} \] (median percent change: \(-32.2\% \) vs. \(-0.6\%\), \(P=0.02\)).

Another interesting observation about the association of LCBI with response to intensive statin therapy was reported by a sub-analysis of YELLOW trial (65) (Tables 6, 7). This therapeutic regimen did not alter lipid component at coronary atheroma harbouring LCBI
\[\text{max 4 mm} <500\], whereas a marked reduction of LCBI
\[\text{max 4 mm} \geq 500\] was observed at lesions under 20 mg rosuvastatin use (median: 703 at baseline, 399 at 7 weeks, \(P=0.004\)). As such, serial NIRS imaging provides a novel opportunity to elucidate the efficacy of therapies as well as the mechanism behind its efficacy.

**Consideration of limitation of NIRS imaging**

Near-infrared light reaches around 3 mm far from the center of catheter. Therefore, NIRS could provide information of lipidic plaque component at shallow depth. It may be difficult to evaluate lipidic features at deeper area in depth.

Validation study did not evaluate NIRS imaging at lesions with thrombus at its surface. Whether the presence of thrombus affects NIRS signals remains to be determined yet.

**Coronary angioscopy**

**Validation of coronary angioscopy imaging**

Coronary angioscopy enables to directly visualize color and morphological characteristics of plaque surface in vivo. Validation study has been conducted by comparing with coronary specimens retrieved by atherectomy catheter (66). In this analysis, white colored plaque mainly corresponded...
to fibrous lesion. Additionally, yellow colored plaque was more likely to associate with atheroma containing necrotic tissue.

**The ability of coronary angioscopy imaging for future cardiovascular events (Tables 8,9)**

The association of yellow plaques on coronary angioscopy with future risk of ACS has been reported in 2006 (68). A total of 552 subjects with suspected or diagnosed CAD who received coronary angioscopy were analyzed. During the observational period (57.3±22.1 months), patients who experienced the occurrence of ACS were more likely to have a greater number of yellow plaques at baseline (3.1±1.8 vs. 2.2±1.5, P=0.008). Multivariate logistic regression analysis revealed number of yellow plaques as an independent risk factors of ACS events (adjusted hazard ratio =1.23, 95% CI: 1.03–1.45, P=0.02).

**Table 8 Clinical studies with coronary angioscopy imaging—prediction of future cardiovascular events**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Cites</th>
<th>Population</th>
<th>NIRS-derived measure</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ohtani, et al.</td>
<td>(68)</td>
<td>552 patients with suspected or diagnosed CAD</td>
<td>Number of yellow plaques within the culprit vessel</td>
<td>During the observational period (57.3±22.1 months), patients who experienced the occurrence of ACS were more likely to have a greater number of yellow plaques at baseline (3.1±1.8 vs. 2.2±1.5, P=0.008). Multivariate logistic regression analysis revealed number of yellow plaques as an independent risk factors of ACS events (adjusted hazard ratio =1.23, 95% CI: 1.03–1.45, P=0.02)</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval.

**Table 9 Clinical studies with coronary angioscopy imaging—evaluation of drug efficacy**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Population</th>
<th>Drug</th>
<th>Outcome</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takano, et al.</td>
<td>31 patients with CAD</td>
<td>Atorvastatin vs. diet therapy</td>
<td>Change in the mean yellow score</td>
<td>In the atorvastatin group, a reduction of the mean yellow score was observed (from 2.03±0.45 to 1.13±0.33, P&lt;0.0001), whereas diet therapy was associated with its increase during 1-year observational period (from 1.67±0.62 to 1.99±0.61, P=0.04)</td>
</tr>
<tr>
<td>Kodama, et al.</td>
<td>46 patients with CAD</td>
<td>2 mg pitavastatin</td>
<td>Change in yellow grade</td>
<td>Following 52-week pitavastatin use, yellow grade significantly decreased (from 2.9±0.8 to 2.6±0.7, P=0.04).</td>
</tr>
<tr>
<td>Ueda, et al.</td>
<td>131 patients with stable CAD</td>
<td>10–20 mg atorvastatin + ezetimibe vs. 10–20 mg atorvastatin alone</td>
<td>Change in yellow color grade</td>
<td>In both groups, a significant reduction of yellow color grade was observed (atorvastatin + ezetimibe: 2.1±1.1 vs. 1.7±1.0, P=0.005, atorvastatin: 2.2±1.2 vs. 1.8±1.2, P=0.002). These favourable changes did not differ between the groups (P=0.60)</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval.

**Drug efficacy assessment study with coronary angioscopy (Tables 8,9)**

Takano *et al.* compared change in plaque colour between atorvastatin therapy and diet therapy in 31 patients with CAD (69). During the 12-month observational period, atorvastatin therapy induced a significant decrease in mean yellow score (P=0.002). Similar finding was reported by the TOGETHER trial which investigated the efficacy of pitavastatin on yellow plaques (70). In this study, the use of 2 mg pitavastatin for 52 weeks was associated with a reduction of yellow grade (2.9±0.8 to 2.6±0.7, P=0.04). Ueda *et al.* used coronary angioscopy to elucidate the efficacy of ezetimibe on yellow plaques (ZIPANGU study: Ezetimibe clinical investigation for the regression of intracoronary plaque evaluated by angioscopy and ultrasound) (71). This study randomized 131 stable CAD patients to atorvastatin + ezetimibe or atorvastatin alone. Serial coronary angioscopy demonstrated that the extent of yellow colour reduction was similar in both groups.

**Consideration of limitation of coronary angioscopy imaging**

Since it is required to remove blood for imaging, continuous infusion of low-molecular-weight dextran is continuously infused. Visualized area on coronary angioscopy is limited,
and therefore, this modality can not visualize all of plaques within vessel wall. Yellow colour assessment is a subjective measure. This limitation suggests that yellow colour grade may be different between each physician.

**Comparison of each imaging modality**

As mentioned above, VH-IVUS, IB-UVUS, OCT, NIRS and coronary angioscopy are similar to visualize vulnerable plaque. In addition, it is important to understand the following differences in each modality for better selection and interpretation of images.

**Imaging procedure**

OCT and coronary angioscopy requires the continuous infusion of contrast medium or low-molecular-weight dextran for its imaging, whereas others do not. This technical aspect could affect the quality of acquired images.

**Measurement of vessel dimensions**

Values of measurement about vessel and lumen diameter is different between VH-IVUS, IB-IVUS and OCT, whereas NIRS and coronary angioscopy does not provide any information of vessel and lumen sizes. In detail, although the measurements of vessel dimensions on OCT is significantly correlated to those on VH-IVUS and IB-IVUS, their small differences exist (11–22%). In particular, the interventionalist has to recognize that lumen area measured by OCT is normally smaller than IVUS-derived one (72).

**Visualization of plaque compositions**

VH-IVUS, IB-IVUS, OCT and coronary angioscopy shows a variety of plaque components/structures, whereas NIRS evaluates only the degree of lipidic plaque materials.

**Evaluation of TCFA**

One study showed the discrepancy of TCFA between VH-IVUS and OCT (73). In this analysis, there were 61 VH-IVUS derived and 36 OCT-derived TCFA. Of these, only 28 lesions fulfilled both VH-IVUS and OCT based TCFA definition. The remaining 33 VH-IVUS TCFA did not exhibit thin-cap on OCT, and 8 OCT TCFA exhibited less than 10% of necrotic core areas in contact with the lumen.

**Quantitative analysis of plaque composition**

VH-IVUS and IB-IVUS measure the volume of each plaque component. NIRS enables to provide quantitative measurement of lipidic plaque materials. By contrast, the assessment of plaque component, especially lipid plaque on OCT and plaque colour grade on coronary angioscopy are subjective.

**Future directions**

While the currently available intravascular imaging modalities provide a variety of anatomical information of coronary atheroma in vivo, recent studies indicate not only anatomical data but also other plaque-related characteristics as another important contributor to plaque vulnerability. For instance, Costopoulos et al. reported the association of plaque structural stress and wall shear stress with plaque vulnerability and progression (74). In this analysis, high plaque structural stress and low wall shear stress were associated with an increased vulnerability and plaque progression, respectively.

Another potential feature of plaques is its biological functionality (75). Intravascular near-infrared fluorescence is a novel imaging approach which uses protease-activated fluorescence agent. Pre-clinical study has shown this imaging technique visualized inflammation within vessel wall of rabbit atherosclerosis model (76). Although further clinical studies are warranted to elucidate the feasibility and safety of intravascular imaging of plaque inflammation, visualization of plaque activity will be also important to predict future cardiovascular risks. In the future, by collecting anatomical as well as biomechanical and functional data of coronary plaques, it may be possible to establish novel therapeutic approach to stabilize vulnerable plaque, thereby leading to the prevention of ACS.

**Conclusions**

The accumulating evidence from clinical studies have shown intravascular imaging of vulnerable plaques as a great potential tool for predicting future risk of cardiovascular events and evaluating the efficacy of novel agents. However, it is important to recognize that not only anatomical plaque features but also biomechanical factors as well as functionality of plaques could play important roles in driving plaque instability. In addition, a variety of
biomarkers reflecting pathophysiology of atherosclerosis may help to assess the degree of vulnerability at coronary lesions. Given that technological advances such as machine learning and/or artificial intelligence are rapidly progressing, these technologies are expected to create sophisticated tool which collects anatomical, biomechanical and functional imaging data of coronary atheroma in conjunction with biomarkers. This novel but ideal approach will be useful in refining the degree of plaque vulnerability, which enables to adopt individualizing therapy for further reduction of future coronary event’s risk.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Provenance and Peer Review:** This article was commissioned by the Guest Editor (Dennis T. L. Wong) for the series “Intracoronary Imaging” published in *Cardiovascular Diagnosis and Therapy*. The article was sent for external peer review organized by the Guest Editor and the editorial office.

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt-20-238). The series “Intracoronary Imaging” was commissioned by the editorial office without any funding or sponsorship. YK serves as an unpaid editorial board member of *Cardiovascular Diagnosis and Therapy* from Jul 2019 to Jun 2021. The authors have no other conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


